Nursing Elites

1. In a postmenopausal woman, what condition can be prevented by administering estradiol (Estraderm)?

• A. Endometriosis
• B. Amenorrhea
• C. Osteoporosis
• D. Uterine cancer

Correct answer: C

Rationale: The correct answer is C: Osteoporosis. Estradiol, a form of estrogen, is used to prevent osteoporosis in postmenopausal women by maintaining bone density. Choice A, Endometriosis, is incorrect as estradiol is not used to prevent or treat this condition. Choice B, Amenorrhea, is not prevented by estradiol but rather may result from hormonal changes. Choice D, Uterine cancer, is not directly prevented by estradiol; in fact, long-term unopposed estrogen use can increase the risk of uterine cancer.

2. Which of the following describes the condition in the body of clients experiencing hypovolemia?

• A. Increased urine retention
• B. Insufficient circulating blood volume
• C. Bounding peripheral pulses
• D. Crackles auscultated in the lungs

Correct answer: B

Rationale: The correct answer is B: Insufficient circulating blood volume. Hypovolemia is a condition characterized by a decrease in the volume of blood plasma. This reduction in circulating blood volume can lead to inadequate perfusion of tissues and organs, potentially resulting in shock if left untreated. Choices A, C, and D are incorrect because increased urine retention, bounding peripheral pulses, and crackles auscultated in the lungs are not typical manifestations of hypovolemia.

3. How does influenza immunization produce immunity?

• A. The virus from the vaccine remains in the body until the end of the season
• B. An attenuated virus causes immune system suppression and triggers immunity
• C. The body identifies the virus and develops antibodies against the virus
• D. The vaccine remains in the injection site and produces immune cells

Correct answer: C

Rationale: The correct answer is C. Influenza immunization works by introducing a weakened or inactivated form of the virus into the body, allowing the immune system to recognize it as foreign. This recognition triggers the production of antibodies specific to the virus. Choice A is incorrect as the virus in the vaccine does not remain in the body until the end of the season. Choice B is incorrect as an attenuated virus does not cause immune system suppression but rather stimulates an immune response. Choice D is incorrect because the vaccine does not stay at the injection site but rather prompts a systemic immune response throughout the body.

4. A patient presents with a chronic cough, night sweats, and weight loss. A chest X-ray reveals upper lobe cavitary lesions. Which of the following is the most likely diagnosis?

• A. Tuberculosis
• B. Pneumonia
• C. Lung cancer
• D. Sarcoidosis

Correct answer: A

Rationale: The correct answer is A: Tuberculosis. Cavitary lesions in the upper lobes are classic findings seen in tuberculosis. This infectious disease commonly presents with symptoms such as chronic cough, night sweats, and weight loss. Pneumonia (Choice B) typically does not present with cavitary lesions on chest X-ray. Lung cancer (Choice C) may present with similar symptoms but is less likely to cause cavitary lesions in the upper lobes. Sarcoidosis (Choice D) usually presents with bilateral hilar lymphadenopathy and non-caseating granulomas, different from the cavitary lesions described in the case.

5. A male patient is receiving testosterone therapy for hypogonadism. What adverse effect should the nurse be most concerned about?

• A. Increased risk of breast cancer
• B. Increased risk of liver dysfunction
• C. Increased risk of cardiovascular events
• D. Increased risk of prostate cancer

Correct answer: C

Rationale: The correct answer is C: Increased risk of cardiovascular events. Cardiovascular events such as stroke and myocardial infarction are the most concerning adverse effects of testosterone therapy, especially in older patients. Choice A, increased risk of breast cancer, is not a common adverse effect of testosterone therapy in males. Choice B, increased risk of liver dysfunction, is a potential adverse effect but is not the most concerning. Choice D, increased risk of prostate cancer, is a consideration in patients with a history of prostate cancer or those with prostate carcinoma, not typically in patients receiving testosterone therapy for hypogonadism.

Similar Questions